1 High-Risk Penny Stock That May Be Worth Buying
Penny stocks, or stocks with a sub-$5 share price, generally aren't my cup of tea. These types of companies tend to be far too risky to make them worthy of serious investment consideration. The oncology specialist Geron (NASDAQ: GERN), however, has piqued my interest of late -- even though the company's share price is presently hovering around $2.
While I fully admit that there are a couple of solid reasons to fear that thus speculative biotech could well end up going bankrupt, the stock's monstrous upside potential has my full attention ahead of what could be a major clinical update at the American Society of Hematology meeting later this month. So without further ado, here's why I think this penny stock may be worth buying right now.
Image Source: Getty Images.
Source: Fool.com
Geron Corp. Aktie
Eine Reihe von Buy-Einschätzungen für Geron Corp., keine Sell-Einschätzungen in Sicht.
Das Kursziel von 5 € für Geron Corp. weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 4.02 € hin.
